ClinicalTrials.gg

Program

N-Acetylcysteinamide

Also written as “NPI-001”, “N-Acetylcysteine Amide” and “NACA”.

Its studies are mostly in Usher Syndromes · Cystinosis · Cognitive Dysfunction · Cerebral Amyloid Angiopathy, Familial, led by 2 companies.

Furthest: phase 3, since Dec 16, 20256 company-led studies, 4 open or runningNext primary completion: Dec 29, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nacuity Pharmaceuticals42 open or runningphase 3since Dec 16, 2025Apr 17, 2020Apr 2029phase 3 · NCT07710196
Arctic Therapeutics22 open or runningphase 2since Mar 18, 2026Mar 18, 2026Dec 29, 2026phase 2 · NCT07716865

Also a collaborator on its studies: blueskin-as.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 17, 2020First study: phase 2 study in Usher SyndromesNew to Nacuity PharmaceuticalsNacuity Pharmaceuticals · NCT04355689 · 49 enrolled · Australia
  2. Aug 8, 2023Phase 2 study in CystinosisNacuity Pharmaceuticals · NCT05994534 · 8 enrolled · Australia
  3. Dec 16, 2025Phase 3 study in Retinitis PigmentosaPhase 3 reachedNacuity Pharmaceuticals · NCT07290530 · 80 planned
  4. Mar 18, 2026Arctic Therapeutics's first studies: 2 phase 2 studiesNew to Arctic TherapeuticsArctic Therapeutics · NCT07741526, NCT07716865
  5. Jul 13, 2026Phase 3 study in Retinitis PigmentosaNacuity Pharmaceuticals · NCT07710196 · 80 planned · United States

Ahead

  1. Dec 29, 2026Primary completion: phase 2 study in Cerebral Amyloid Angiopathy, FamilialArctic Therapeutics · NCT07716865
  2. Apr 30, 2027Primary completion: phase 2 study in Cognitive DysfunctionArctic Therapeutics · NCT07741526
  3. Apr 2029Primary completion: phase 3 study in Retinitis PigmentosaNacuity Pharmaceuticals · NCT07710196
  4. Jul 2029Primary completion: phase 3 study in Retinitis PigmentosaNacuity Pharmaceuticals · NCT07290530

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07710196Retinitis Pigmentosa · United States3RecruitingNacuity PharmaceuticalsApr 202980
NCT07741526Cognitive Dysfunction · Denmark, Iceland2Active, not recruitingArctic TherapeuticsApr 30, 202733
NCT07716865Cerebral Amyloid Angiopathy, Familial · Iceland2Active, not recruitingArctic TherapeuticsDec 29, 202615
NCT07290530Retinitis Pigmentosa3Not yet recruitingNacuity PharmaceuticalsJul 202980
NCT05994534Cystinosis · Australia2CompletedNacuity PharmaceuticalsMay 26, 20268
NCT04355689Usher Syndromes · Australia2CompletedNacuity PharmaceuticalsJun 20, 202549

How it is read

Names in the registry

  • “NPI-001”, 3 entries
  • “N-Acetylcysteine Amide”, 1 entry
  • “NACA”, 1 entry
  • “N-acetylcysteine amide”, 1 entry

Codes read as this program: NPI001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.